Integrated care for alcohol use and alcohol-related liver disease
Integrated therapies for alcohol use and ALD (ITAALD) Network – UTSW Clinical Center
['FUNDING_U01'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-11195095
This program combines medical treatments and addiction support to help people with alcohol-related liver disease, including those with severe alcohol-associated hepatitis.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-11195095 on ClinicalTrials.gov |
What this research studies
You would be treated by a team that addresses both your liver disease and alcohol use together rather than separately. The network tests medical therapies (including newer drugs like IL-22 and options used for alcohol use disorder such as acamprosate, and uses steroids in certain severe cases) alongside behavioral therapy like motivational interviewing. Parts of the program use randomized trials at participating centers to compare treatments, while other parts coordinate integrated clinical care across sites. The aim is to reduce drinking, improve liver recovery, and lower short-term death from severe alcohol-associated hepatitis.
Who could benefit from this research
Good fit: Adults with alcohol-associated liver disease—especially those hospitalized with severe alcohol-associated hepatitis and/or diagnosed alcohol use disorder—who can consent and attend participating centers.
Not a fit: People without alcohol-related liver disease, those with liver disease from other causes, or those unable or unwilling to engage in integrated addiction care are unlikely to benefit from this program.
Why it matters
Potential benefit: If successful, this approach could lower short-term deaths from severe alcohol-associated hepatitis, improve liver recovery, and help people stay sober longer.
How similar studies have performed: A previous trial unexpectedly found very high short-term survival with prednisone in severe alcohol-associated hepatitis suggesting promising signals that need confirmation, while behavioral therapies and medications like acamprosate have helped people with alcohol use disorder in other settings but are less studied in severe ALD.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MITCHELL, MACK CLARENCE — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: MITCHELL, MACK CLARENCE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alcoholic Liver Diseases